What this means
A trial is testing an AI tool that checks eyes for diabetes and macular eye damage. It has not reported results, so we do not yet know if it works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 20 and over
- Where
- 1 site
The science
- Registered title
- Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics
- Trial ID
- NCT07069647 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR)
- What is tested
- VeriSee AI-assisted screening tools for diabetic retinopathy and age-related macular degeneration, Standard fundus photography with physician interpretation
- Sponsor
- National Taiwan University Hospital
- Ages
- 20 Years to no maximum
- Dates
- First posted Jul 17, 2025 · updated Jul 22, 2026
Registry summary
Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are leading causes of vision loss, with rising incidence due to aging populations and increasing diabetes prevalence. However, delayed diagnoses are common due to low disease literacy and lack of dedicated screening tools in internal medicine. This multi-center RCT at National Taiwan University Hospital evaluates the clinical effectiveness and cost-effectiveness of the VeriSee AI-assisted diagnostic software for DR and AMD screening. Participants include adults with diabetes and individuals aged 50 and above meeting AMD screening criteria, randomized to AI-assisted screening with immediate physician explanation or standard physician-only screening. Primary outcomes include detection rates of DR and AMD, ophthalmology referral outcomes, and patient/physician satisfaction. Data collection will occur from April 2025 to December 2027. This study aims to provide evidence on the clinical utility of AI-assisted ophthalmic screening in improving early detection, facilitating timely treatment, and reducing severe visual impairment and healthcare burdens in real-world clinical settings.
Sites (1)
- National Taiwan University Hospital, Taipei, Taiwan